US 2015/0018358 A1 - Compositions And Methods For Treating Purpura - The Lens

Compositions And Methods For Treating Purpura

Published: Jan 15, 2015
Earliest Priority: Nov 16 2007
Family: 30
Cited Works: 0
Cited by: 0
Cites: 0
Additional Info: Full text

Abstract

Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Preferred compositions comprise an α adrenergic receptor agonist selected from selective α1 adrenergic receptor agonist, selective α2 adrenergic receptor agonist, non-selective α1/α2 adrenergic receptor agonist, agents with α2 adrenergic receptor agonist activity and combinations thereof, in a pharmaceutically acceptable carrier in order to treat and improve the cosmetic appearance of hemorrhagic (purpuric) lesions in the skin.

Claims

A method for treating or preventing non-thrombocytopenic purpura in a subject undergoing a procedure, the method comprising:
administering to the subject a therapeutically effective amount of an α adrenergic receptor agonist selected from a selective α₁adrenergic receptor agonist, a selective α₂adrenergic receptor agonist and combinations thereof;

wherein the procedure is a procedure involving physical trauma to the skin and/or cutaneous vasculature.
The method of claim 1, wherein the procedure comprises the injection of a neurotoxin or filler for soft-tissue augmentation.
The method of claim 1, wherein the procedure comprises the injection of a filler for soft-tissue augmentation.
The method of claim 1, wherein the α adrenergic receptor agonist is administered before, during or after the procedure.
The method of claim 4, wherein the α adrenergic receptor agonist is administered during the procedure.
The method of claim 1, wherein the α adrenergic receptor agonist is administered by injection.
The method of claim 6, wherein the α adrenergic receptor agonist is administered before, during or after the procedure.
The method of claim 7, wherein the α adrenergic receptor agonist is administered during the procedure.
The method of claim 1, wherein the purpura comprises petechiae or ecchymoses.
The method of claim 1, wherein the α adrenergic receptor agonist is selected from oxymetazoline, naphazoline, tetrahydrozoline, phenylephrine, xylometazoline, methoxamine, metaraminol, midodrine, desglymidodrine, cirazoline, amidephrine, brimonidine, clonidine, guanfacine, guanabenz, apraclonidine, xylazine, medetomidine, dexmedetomidine, amethyldopa, epinephrine, norepinephrine, isoproterenol, dipivefrin, pseudoephedrine, mephentermine, phenylpropanolamine, propylhexadrine, amphetamine, dextroamphetamine, ephedrine, epinine, ethylnorepinephrine, levarterenol, lofexidine, methamphetamine, α-methylnorepinephrine, methylphenidate, mivazerol, moxonidine, norepinephrine, norphenylephrine, pemoline, tizanidine and combinations thereof.
The method of claim 1, wherein the α adrenergic receptor agonist is α₁adrenergic receptor agonist.
The method of claim 11, wherein the α₁adrenergic receptor agonist is selected from the group of α₁adrenergic receptor agonists consisting of oxymetazoline, naphazoline, tetrahydrozoline, phenylephrine, xylometazoline, methoxamine, metaraminol, midodrine, desglymidodrine, cirazoline, and amidephrine.
The method of claim 12, wherein the α₁adrenergic receptor agonist is phenylephrine.
The method of claim 1, wherein the α adrenergic receptor agonist is α₂adrenergic receptor agonist.
The method of claim 14, wherein the α₂adrenergic receptor agonist is selected from the group of α₂adrenergic receptor agonists consisting of brimonidine, clonidine, guanfacine, guanabenz, apraclonidine, xylazine, medetomidine, dexmedetomidine, and α-methyldopa.
The method of claim 15, wherein the α₂adrenergic receptor agonist is brimonidine.
The method of claim 1, wherein the administering is performed by injection of a formulation comprising the α adrenergic receptor agonist and a polymeric material.
The method of claim 1, wherein the administering is performed by injection of a formulation comprising the α adrenergic receptor agonist and a gel phase carrier.
The method of claim 18, wherein the gel phase carrier comprises a material selected from the group of materials comprising calcium carbonate, calcium phosphate, a sugar, a starch, a cellulose derivative, a gelatin, and a polymer.
The method of claim 19, wherein the gel phase carrier comprises a sugar.
A method for preventing non-thrombocytopenic purpura in a subject undergoing injection of a filler for soft tissue augmentation, the method comprising:
administering to the subject a therapeutically effective amount of an α adrenergic receptor agonist selected from a selective α₁adrenergic receptor agonist, a selective α₂adrenergic receptor agonist and combinations thereof.
The method of claim 21, wherein the α adrenergic receptor agonist is administered before, during or after the injection of the filler.
The method of claim 21, wherein the α adrenergic receptor agonist is administered during the injection of the filler.
The method of claim 21, wherein the α adrenergic receptor agonist is administered by injection during injection of the filler.
The method of claim 21, wherein the purpura comprises petechiae or ecchymoses.
The method of claim 21, wherein the α adrenergic receptor agonist is selected from oxymetazoline, naphazoline, tetrahydrozoline, phenylephrine, xylometazoline, methoxamine, metaraminol, midodrine, desglymidodrine, cirazoline, amidephrine, brimonidine, clonidine, guanfacine, guanabenz, apraclonidine, xylazine, medetomidine, dexmedetomidine, amethyldopa, epinephrine, norepinephrine, isoproterenol, dipivefrin, pseudoephedrine, mephentermine, phenylpropanolamine, propylhexadrine, amphetamine, dextroamphetamine, ephedrine, epinine, ethylnorepinephrine, levarterenol, lofexidine, methamphetamine, α-methylnorepinephrine, methylphenidate, mivazerol, moxonidine, norepinephrine, norphenylephrine, pemoline, tizanidine and combinations thereof.
The method of claim 21, wherein the α adrenergic receptor agonist is α₁adrenergic receptor agonist.
The method of claim 27, wherein the α₁adrenergic receptor agonist is selected from the group of α1 adrenergic receptor agonists consisting of oxymetazoline, naphazoline, tetrahydrozoline, phenylephrine, xylometazoline, methoxamine, metaraminol, midodrine, desglymidodrine, cirazoline, and amidephrine.
The method of claim 28, wherein the α₁adrenergic receptor agonist is phenylephrine.
The method of claim 21, wherein the α adrenergic receptor agonist is α₂adrenergic receptor agonist.
The method of claim 30, wherein the α₂adrenergic receptor agonist is selected from the group of α2 adrenergic receptor agonists consisting of brimonidine, clonidine, guanfacine, guanabenz, apraclonidine, xylazine, medetomidine, dexmedetomidine, and α-methyldopa.
The method of claim 31, wherein the α₂adrenergic receptor agonist is brimonidine.
The method of claim 21, wherein the administering is performed by injection of a formulation comprising the α adrenergic receptor agonist and a polymeric material.
The method of claim 21, wherein the administering is performed by injection of a formulation comprising the α adrenergic receptor agonist and a gel phase carrier.
The method of claim 34, wherein the gel phase carrier comprises a material selected from the group of materials comprising calcium carbonate, calcium phosphate, a sugar, a starch, a cellulose derivative, a gelatin, and a polymer.
The method of claim 35, wherein the gel phase carrier comprises a sugar.
A composition for treating or preventing non-thrombocytopenic purpura in a subject undergoing injection of a filler for soft tissue augmentation, the composition comprising:
a gel phase carrier; and

a therapeutically effective amount of an α adrenergic receptor agonist selected from a selective α₁adrenergic receptor agonist, a selective α₂adrenergic receptor agonist and combinations thereof.
The composition of claim 37, wherein the α adrenergic receptor agonist is selected from oxymetazoline, naphazoline, tetrahydrozoline, phenylephrine, xylometazoline, methoxamine, metaraminol, midodrine, desglymidodrine, cirazoline, amidephrine, brimonidine, clonidine, guanfacine, guanabenz, apraclonidine, xylazine, medetomidine, dexmedetomidine, amethyldopa, epinephrine, norepinephrine, isoproterenol, dipivefrin, pseudoephedrine, mephentermine, phenylpropanolamine, propylhexadrine, amphetamine, dextroamphetamine, ephedrine, epinine, ethylnorepinephrine, levarterenol, lofexidine, methamphetamine, α-methylnorepinephrine, methylphenidate, mivazerol, moxonidine, norepinephrine, norphenylephrine, pemoline, tizanidine and combinations thereof.
The composition of claim 37, wherein the α adrenergic receptor agonist is α₁adrenergic receptor agonist.
The composition of claim 37, wherein the α₁adrenergic receptor agonist is selected from the group of α₁adrenergic receptor agonists consisting of oxymetazoline, naphazoline, tetrahydrozoline, phenylephrine, xylometazoline, methoxamine, metaraminol, midodrine, desglymidodrine, cirazoline, and amidephrine.
The composition of claim 40, wherein the α₁adrenergic receptor agonist is phenylephrine.
The composition of claim 37, wherein the α adrenergic receptor agonist is α₂adrenergic receptor agonist.
The composition of claim 42, wherein the α₂adrenergic receptor agonist is selected from the group of α₂adrenergic receptor agonists consisting of brimonidine, clonidine, guanfacine, guanabenz, apraclonidine, xylazine, medetomidine, dexmedetomidine, and α-methyldopa.
The composition of claim 43, wherein the α₂adrenergic receptor agonist is brimonidine.